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Abstract 
  
Aim 
To examine the performance of 18F-FDG PET/MRI in the loco-regional staging of malignant 
pleural mesothelioma (MPM).  
Methods 
Consecutive subjects with MPM undergoing pre-operative staging with 18F-FDG PET/CT who 
underwent a same day integrated 18F-FDG PET/MRI were prospectively studied. Clinical 
TNM staging (AJCC 7th edition) was performed separately and in consensus by two readers 
on the 18F-FDG PET/MRI studies, and compared with staging by 18F-FDG PET/CT, and with 
final pathological stage, determined by a combination of intra-operative and histological 
findings. 
Results 
10 subjects (9 male, mean age 68 years) with biopsy-proven MPM (9 epithelioid tumours, 1 
biphasic) were included. One subject underwent neo-adjuvant chemotherapy between 
imaging and surgery and was excluded from the clinical versus pathological stage analysis. 
Pathological staging was concordant with staging by 18F-FDG PET/MRI in 67% (n=6) of 
subjects, and with 18F-FDG PET/CT staging in 33% (n=3). Pathological T stage was concordant 
with 18F-FDG PET/MRI in 78% (n=7), and with 18F-FDG PET/CT in 33% (n=3) of subjects. 
Pathological N stage was concordant with both 18F-FDG PET/MRI and 18F-FDG PET/CT in 78% 
(n=7) of cases. No subject had metastatic disease. There was good inter-observer 
agreement for overall PET/MRI staging (weighted kappa 0.63) with moderate inter-reader 
agreement for T staging (weighted kappa 0.59). All 6 subjects with prior talc pleurodesis 
demonstrated mismatch between elevated FDG uptake and restricted diffusion in areas of 
visible talc deposition.   
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Conclusion 
Clinical MPM staging by 18F-FDG PET/MRI is feasible, and potentially provides more accurate 
loco-regional staging than PET/CT, particularly in T staging. 
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Abbreviations 
ADC-apparent diffusion coefficient  
AJCC-American Joint Committee on Cancer 
CT-computed tomography 
DWI-diffusion-weighted imaging 
FDG-2-deoxy-2-[18F]fluoro-D-glucose 
HASTE= half Fourier-acquired single shot turbo spin echo 
IMIG-International Mesothelioma Interest Group  
IASLC-International Association for the Study of Lung Cancer  
IV-intravenous 
MRI-magnetic resonance imaging 
MPM-malignant pleural mesothelioma  
MPR-multiplanar reformats 
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PET-positron emission tomography  
ROI-region of interest 
SD-standard deviation 
SUVmax-maximum standardised uptake value  
TGV-total glycolytic volume 
TNM-tumour, nodes and metastasis  
VIBE-volume-interpolated breath-hold examination 
 
Introduction 
 
Malignant pleural mesothelioma (MPM) is the most common primary malignant tumour of 
the pleura, arising from mesothelial cells [1]. Despite recent advances in tri-modality 
treatment (surgery, chemotherapy and radiotherapy), the prognosis remains dismal, with a 
five year survival of less than 10% [2].   
 
Accurate staging is important to triage patients down the appropriate treatment pathway 
[3].  MPM has a complex morphology, with a rind-like appearance like that of the skin of an 
orange, growing across multiple imaging planes and crossing multiple tissue boundaries. The 
currently most widely used clinical staging system is the International Association for the 
Study of Lung Cancer (IASLC) and the International Mesothelioma Interest Group (IMIG)  
tumour, nodes and metastasis (TNM) system [4-6]. Due to the complex growth pattern in 
MPM, the current T stage descriptors rely on a qualitative, descriptive assessment of the 
extent of local tumour invasion. Qualitative assessment of tumour extension through local 
structures such as the diaphragm, pericardium and chest wall can be hard to perform 
accurately and reproducibly with CT [1,7,8].   
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MRI provides excellent soft tissue resolution, and is a potentially useful modality for MPM 
diagnosis and staging, but is not in widespread use [1]. The main strength of 2-deoxy-2-
[18F]fluoro-D-glucose (FDG) positron emission tomography-computed tomography (PET/CT) 
in MPM clinical staging is in its ability to detect distal and occult metastases. Additionally, 
FDG PET does provide functional information, such as metabolic activity or metabolic 
tumour volume, which may be prognostic [9,10]. However, it contributes little to local T 
staging above contrast enhanced CT [11].  
 
Novel integrated PET/MRI systems have the potential to marry the superior soft tissue 
resolution and multi-parametric capabilities of MRI with the metabolic information provided 
by FDG PET in a single examination.  A published series of six MPM patients by 
Schaarschmidt et al. has demonstrated that integrated PET/MRI is non-inferior to PET/CT in 
TNM staging of MPM [12]. Our hypothesis is that FDG PET/MRI is feasible in loco-regional 
staging of MPM, and may be superior to FDG PET/CT. The aim of our prospective study is to 
examine how integrated PET/MRI performs in loco-regional MPM staging, using pathological 
staging as the reference standard. 
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Materials & Methods 
Patients 
This prospective study was approved by a research ethics committee and all subjects gave 
informed consent. All pre-operative patients referred for clinical FDG PET/CT staging for 
malignant pleural mesothelioma  were considered for inclusion in this prospective single 
centre study. To fulfil inclusion criteria, subjects had to have a histological confirmed 
diagnosis of MPM, be potential operative candidates and have no contraindications to MRI. 
Ten patients (9 men, 1 woman, mean age of 68 ± 6.1 years with a range 51-73 years) and 
biopsy proven MPM consented to take part in the study. They had a single dose of 
radiotracer administered and underwent a same-day on-site FDG PET/MRI immediately 
following the clinical PET/CT scan. Final pathological TNM staging (7th edition) after surgical 
intervention was used as the gold standard for staging comparison. 
 
18FDG PET/CT acquisition  
18FDG PET/CT scans were all acquired in our institution using the same standard clinical 
protocol on one of two scanners (Discovery 710, GE Healthcare, Chicago, IL, USA). Patients 
were fasted for a minimum of 6 hours.  A standard PET acquisition from skull base to upper 
thighs was acquired 60-90 minutes post-injection of 350MBq (± 10%) of FDG. Image 
acquisition was performed with a field of view covering the head to mid-thigh using a 
setting of 3 min per bed position for five to eight bed positions. Images were reconstructed 
using the ordered subsets expectation maximisation algorithm with a reconstructed slice 
thickness of 3.27 mm and pixel size of 4.7 mm. A CT was acquired for attenuation correction 
and anatomic localisation at 140 kVp and Smart mA (15-100) without administration of oral 
or intravenous contrast agent. 
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18FDG PET/MRI acquisition  
18FDG PET/MRI examinations were performed on a same-site integrated PET/MRI system 
(Siemens Biograph mMR, Erlangen, Germany), capable of simultaneous PET and MR imaging 
in one examination. This was performed immediately after the PET/CT using residual tracer 
activity. PET/MRI was acquired from the skull base to mid-thigh (total of 4-5 bed positions, 4 
minutes per bed position). For each bed position a 2-point Dixon volume-interpolated 
breath-hold examination (VIBE) sequence was applied to derive an attenuation map (u-map) 
based on 4 tissue types: air, lungs, soft-tissue and fat.  Other sequences per bed position 
included:  axial T1 Dixon, axial T2 HASTE and axial free breathing diffusion-weighted imaging 
(DWI) sequences (b values: 50 and 900s/mm2). In addition, axial T1 Dixon sequences were 
acquired post administration of 0.1mmol/kg of intravenous gadolinium (Gadobutrol, Bayer 
Healthcare, Leverkusen, Germany). Detailed PET/MRI sequence parameters are displayed in 
Table 1.  
 
Qualitative image analysis 
Qualitative PET/MRI image analysis was performed independently by two fellowship trained 
thoracic radiologists (DJM, SMM) using PET/MRI specific viewing software (SyngoVia, 
Siemens Healthineers, Erlangen, Germany). The two readers, blinded to the PET/CT findings, 
independently assigned a TNM stage for each patient according the 7th edition of the MPM 
TNM staging system. The individual PET/MRI staging results for the two readers were then 
compared directly. As integrated PET/MRI is a novel imaging modality, scans with 
disagreement in TNM staging were discussed and a consensus PET/MRI staging result 
reached. The consensus PET/MRI staging results were then compared with the final 
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pathological TNM stage. By means of an imaging comparison, TNM staging was also blindly 
performed on the clinical FDG PET/CTs by a PET fellowship trained thoracic radiologist 
(DJM)-this was performed separate to the PET/MRI staging, at least 2 weeks apart.  
 
Quantitative image analysis. 
Measurements of tumour metabolic activity was performed by measuring the maximum 
standardised uptake value (SUVmax) on the attenuation corrected PET/MRI and PET/CT 
images. Quantitative image analysis was performed on both the PET/MRI and PET/CT scans 
at a single sitting by a single reader (DJM), at a separate time point to the qualitative staging 
analysis. Mean apparent diffusion coefficient (ADC) values were measured at the 
corresponding sites by manually drawing a region of interest (ROI) on the ADC map, derived 
from the DWI sequence. These measurements were repeated in sample areas of 
macroscopic talc in subjects where talc was visualised on the non-contrast CT component of 
the PET/CT examination. 
 
Surgical technique 
All patients included in the study underwent a surgical biopsy, and either talc pleurodesis or 
indwelling percutaneous catheter placement if a trapped lung was present. For subjects 
deemed surgically resectable, a pleurectomy decortication was performed according to the 
technique described by Rusch et al. [13]. No subject had an extrapleural pneumonectomy 
performed.  Lymph node sampling and biopsy of the diaphragm and/or pericardium were 
performed to increase the accuracy of pathological staging at the time of surgery. 
Diaphragmatic and /or pericardial resection and reconstruction was performed if directly 
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involved by tumour. Six patients (60%) had undergone talc pleurodesis prior to macroscopic 
pleural resection. 
 
Statistical analysis 
Continuous variables are presented as mean ± standard deviation (SD). Categorical variables 
are presented as frequencies and percentages. Inter-observer agreement for PET/MRI TNM 
staging was assessed by the weighted kappa method. Pearson correlation coefficients were 
calculated to examine the relationship between SUVmax and ADCmean values for areas of 
tumour, and for areas of talc deposition. Students independent t-test was used for 
comparison of continuous variables. Statistical analysis was performed using GraphPad 
statistical software (GraphPad Software, La Jolla, CA, USA).  
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Results 
Patients 
Amongst the ten included patients, nine had epithelioid-type tumours, and one had a 
biphasic mesothelioma tumour. The average administered dose of 18F-FDG was 319.8 ± 10.8 
MBq (range 307-345 MBq). The average time period between FDG injection and 
commencement of the clinical PET/CT scan was 69 ± 1 minutes (range 59-91 minutes), with 
an average time delay between radiotracer administration (incorporating the clinical PET/CT 
scan) and commencement of the PET/MRI examination of 124 ± 13 minutes (range 111-158 
minutes). All subjects underwent pleurectomy/decortication. One subject had transmural 
diaphragmatic invasion on pre-operative imaging, and underwent neo-adjuvant 
chemotherapy between imaging and pleurectomy/decortication-this subject is excluded 
from the comparison between imaging and pathological staging. The mean time between 
imaging and surgery for the remaining patients was 14 days (range 3-26 days). 
 
PET/MRI, PET/CT & Pathological Staging 
The complete PET/MRI, PET/CT and pathological staging information for all 10 subjects is 
presented in Table 2. In the nine patients that underwent surgery directly following imaging, 
the overall tumour stage was concordant between PET/MRI and pathological staging in 6 
(67%) of cases, and discordant in 3 (33%). This is higher than the staging results for PET/CT, 
which was concordant with pathological staging in 3 (33%) cases, and discordant in 6 (67%) 
cases. PET/MRI performed better in T staging than PET/CT, and was concordant with 
pathologic T stage in 7 (78%) cases versus 3 (33%) for PET/CT. PET/MRI and PET/CT were 
equivalent in N staging, both were concordant with pathological N stage in 7 (78%) of cases. 
For all 10 subjects imaged, overall tumour staging was concordant between PET/MRI and 
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PET/CT in 7 (70%) of cases, and T stage was concordant in 5 (50%) subjects (Figures 1 & 2) .  
There was good inter-observer agreement for overall PET/MRI tumour stage (weighted 
kappa 0.63) with moderate inter-reader agreement for T stage (weighted kappa 0.59) and N 
stage (weighted kappa 0.52). No subject had evidence of metastatic disease on either 
imaging or pathology. 
 
Quantitative measurements 
The mean PET/MRI derived MPM SUVmax was 5.8 ± 2.7 (range 3.6-12.8), with corresponding 
ADCmean values of 1.02 ± 0.27 10-3 mm2/s (range 0.48-1.50 10-3 mm2/s ). We did not find a 
significant correlation between tumour SUVmax and ADCmean, with a r value of 0.15 (p=0.7).  
Six subjects (60%) had evidence of previous talc pleurodesis on the CT component of their 
FDG PET/CT scans, with corresponding intense FDG uptake. These areas of talc 
accumulation showed relatively increased metabolic activity compared to areas without 
visible talc in these 6 subjects, although this did not achieve statistical significance (mean 
talc SUVmax 7.4 ± 2.1 versus mean tumour SUVmax 4.9 ± 1.7, p=0.06). We observed areas of 
mismatch between FDG uptake on PET and diffusion restriction on DWI in areas of talc 
accumulation in each subject that had evidence of prior talc pleurodesis on CT (Figures 3 & 
4). These foci of visible talc accumulation had significantly higher mean ADC values 
compared to areas of metabolically active tumour (1.78 ± 0.47 10-3 mm2/s  versus 0.98 ± 
0.34 10-3 mm2/s , p=0.007), and we found a moderate positive correlation between talc 
SUVmax and ADCmean with a r value of 0.75, although this did not reach statistical significance 
(p=0.08). 
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Discussion 
In our series, FDG PET/MRI performed well in the loco-regional staging of MPM in 
comparison to pathological staging. PET/MRI performed better than PET/CT in T staging, 
which is often the principal deciding factor of whether a patient is eligible for surgical 
resection [13]. Martini et al. found sequential, co-registered FDG PET + MRI had a 
comparable diagnostic accuracy compared to FDG PET/CT in 34 patients with MPM, 26 with 
histopathological confirmation [14].  Integrated FDG PET/MRI has previously been shown to 
be comparable to FDG PET/CT in MPM staging [12], and our study is the first to compare 
clinical staging by integrated PET/MRI with gold standard pathological staging.  
 
It is unsurprising that FDG PET/MRI was superior to FDG PET/CT in local tumour staging, 
particularly given the superior soft tissue resolution of MRI compared to CT, particularly the 
non-contrast CT component of the PET/CT, which is primarily used for attenuation 
correction and anatomical localisation. Diagnostic quality CT with IV iodinated contrast is 
the main workhorse for MPM clinical staging, but is subject to poor inter-observer variation, 
and tends to underestimate pathological stage in up to 58% of patients [15] [8] [16]. 
Accurately identifying transdiaphragmatic, transpericardial and chest wall invasion is 
challenging on CT, even with the use of multi-planar reformats [17]. MRI has been shown to 
be superior to CT in the identification of occult chest wall, transdiaphragmatic, endothoracic 
fascial and bone invasion [18-20]. The use of gadolinium contrast and fat suppression are 
useful in accurately identifying tumour, helping to distinguish it from pleural fluid and 
adjacent lung, and to identify subtle invasion into the endothoracic fascia, chest wall or 
through the diaphragm, increasing the T stage. Diffusion weighted imaging has been shown 
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to be useful in distinguishing between benign pleural plaques and malignant pleural 
mesothelioma [21], and in the assessment of histological subtypes [22]. 
 
The presence of increased FDG uptake on PET has been proven to be useful in distinguishing 
between benign and malignant pleural disease [23], and FDG PET is excellent at detecting 
occult metastasis [11]. Tumour SUVmax has been proposed as a potential prognostic marker 
[9], and it may also be useful in assessing treatment response [24,25].  The combination of 
FDG PET and MRI in a single examination has the potential to provide a comprehensive, 
complete assessment of local and distant tumour staging in a single examination, giving the 
treating medical and surgical oncology teams the best possible staging information to devise 
the appropriate personalised treatment plan for the individual patient.  
 
One known disadvantage of FDG PET in MPM staging is in the presence of talc pleurodesis, 
where a local  inflammatory reaction to the presence of talc can result in spurious increased 
FDG uptake [26]. Our observation of apparent areas of mismatch between FDG uptake and 
diffusion restriction in areas of talc deposition may be a useful way to discriminate between 
talc and tumour related FDG uptake; this is still only an observation however, and merits 
further investigation in a larger cohort to see if it is a useful clinical sign. We did not find an 
inverse correlation between SUVmax and ADC values in areas of tumour, as was previously 
demonstrated elsewhere [12]. This may be due to the small number of subjects in our 
cohort, and difficulties in measuring ADC values in linear areas of malignant pleural 
thickening due to partial volume averaging. Diffusion restriction has previously been shown 
to be a useful diagnostic and characterisation metric in MPM [21,22], and we observed 
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areas of diffusion restriction with concordant increased FDG uptake in each subject in our 
cohort. 
 
There are potential pitfalls to using FDG PET/MRI as a single staging examination for MPM. 
MRI has an inferior spatial resolution to CT, which may reduce the detection of small pleural 
or pulmonary nodules [27]. Advances in PET/MRI image acquisition may help to overcome 
these difficulties. The development of new, free breathing ultrashort echo time MRI 
sequences greatly improves the quality of pulmonary imaging by MRI over traditional dual 
echo gradient echo imaging, improving the conspicuity of pulmonary and pleural nodules by 
PET/MRI [28]. The use of respiratory triggered PET and MRI image acquisition could also 
improve image quality, leading to improved detection of small sites of pleural or pulmonary 
disease. Respiratory triggered MRI sequences have traditionally been limited by longer 
imaging acquisition times, but novel sequences such as the free-breathing respiratory gated 
T2 weighted PROPELLAR sequence, acquired in approximately 5 minutes, provides 
pulmonary imaging free from breathing artefact, with improved nodule detection compared 
to T1 weighted Dixon sequences [29] [30]. The increased slice thickness of PET/MRI 
compared to PET/CT (typically 4mm for PET/MRI versus 2.5mm for PET/CT) may lead to 
missed lesions due to partial volume averaging, but despite these potential difficulties, we 
did not find any significant missed lesions by FDG PET/MRI, in line with other similar series 
[12,14]. Other potential disadvantages to using PET/MRI include the use of gadolinium 
contrast agents, the length of examination (approximately 60 minutes with our protocol), 
and the large cost and lack of current availability of this new modality. Patients with MPM 
tend to be older, however, and often have breathing difficulties due to pleural disease and 
other pulmonary comorbidities; it is therefore important to try and reduce examination 
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time by rationalising the number of MRI sequences used where possible, and by using free 
breathing sequences [31]. Despite the potential complications of gadolinium, we believe 
that post-contrast imaging is beneficial in MPM staging by PET/MRI, as the fat-saturated 
post contrast MRI images provides superior delineation of local tumour invasion compared 
to CT, particularly in the differentiation of tumour from adjacent fluid, atelectasis and fat 
[20] . Difficulties in performing qualitative staging, and the lack of a quantitative 
component, have led to questions about the consistency and prognostic accuracy of the 
current TNM staging system [32,33], with tumour volume potentially a more accurate 
staging and prognostic metric [15,34,35]. MPM tumour volume measurement performed 
on post-contrast imaging has been shown to be feasible and reproducible by MRI in the 
setting of assessing treatment response [36], with better accuracy than CT [37]. The 
accuracy of tumour volume measurements by MRI could be improved by the addition of a 
map of tumour metabolic activity provided by the PET component of an FDG PET/MRI scan. 
FDG PET also allows derivation of the total glycolytic volume (TGV), a combined measure of 
tumour volume and metabolic activity [38]. TGV appears to be prognostic based on FDG 
PET/CT studies [10,25,39], and if proven to be feasible with FDG PET/MRI, could provide 
additional prognostic information beyond TNM staging, and provide a reproducible imaging 
biomarker for the assessment of metabolic treatment response in clinical trials. The 
acquisition of dynamic-contrast enhanced (DCE) MRI is another potential benefit of 
administering  gadolinium, and appears promising tool for both MPM diagnosis [40] and 
disease response assessment [41]. PET/MRI is a promising new modality, which has the 
potential to provide a comprehensive anatomical and functional examination in a single 
test. 
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Our study has limitations. This was a single site study with a small sample size; PET/MRI is a 
new test and MPM is a relatively rare disease, which made patient recruitment challenging. 
The CT component of the PET/CT scan was acquired without iodinated IV contrast as per our 
routine clinical departmental protocol. This does represent a potential source of bias in 
comparison of the two integrated imaging modalities, but it does represent standard, real-
world clinical practice.  We did not examine the inter-observer agreement for MPM staging 
by FDG PET/CT, as this has been previously performed elsewhere [14]. We performed 
staging according to the 7th edition of AJCC TNM staging manual to ensure uniformity across 
our cohort, as this is what was in operation when our study began in 2015.  The 8th edition 
of the MPM TNM is now in clinical practice, however this is unlikely to influence our results 
significantly, as the differences between the two iterations are small, and do not alter the 
assessment of tumour resectability [4-6]. We acquired axial MRI images only, but both 
readers felt that coronal and sagittal acquisitions would be useful to aid tumour staging, 
particularly when looking for transdiaphragmatic invasion.  
 
In conclusion, our findings suggest that integrated FDG PET/MRI appears feasible for loco-
regional staging of MPM, and may be superior to FDG PET/CT, particularly in determining 
the T stage. In patients who have undergone previous talc pleurodesis, the identification of 
areas of DWI-FDG mismatch may help to distinguish talc-related pleural FDG uptake from 
metabolically active tumour, although this observation requires further investigation in a 
larger cohort to determine its validity.  
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Sequence Region Orientation TR (ms) TE  
(ms) 
Matrix size Slice 
Thickness 
(mm) 
FOV 
(mm) 
Voxel 
Size (mm) 
T1-DIXON WB Axial 4.02 1.23-2.46 175x320 5 430 x 335.9 0.7i x 0.7i x 5 
T2 HASTE WB Axial 700 107 175x320 5 430 x 335.9 0.7i x 0.7i x 5  
DWI (b50, b900 s\mm2) WB Axial 8800 85 132x136 5 430 x 417.4 1.6i x 1.6i x 5 
T1 DIXON + GAD  WB Axial 5.22 2.46-3.69 
 
195x320 2  380 x 308.8 0.6i x 0.6i x 2 
PET WB Axial - - 172 x172 2.03 718 x 718 4.1 x 4.1 x 2.03r  
With interpolation (i) / reconstruction (r) 
 
Table 1. PET/MRI sequence parameters. 
PET=positron emission tomography; MRI=magnetic resonance imaging; FOV=field of view; DWI=diffusion weighted imaging; GAD=intravenous 
gadolinium; WB=whole-body 
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Gender Age Histopathological 
subtype 
TNM stage 
PET/MRI 
TNM Stage 
PET/CT 
TNM Stage 
pathological 
PET/MRI 
stage 
PET/CT 
stage 
Pathological 
stage 
Male 71 Epithelioid  T3 N0 M0 T3 N0 M0 T3 N0 M0 3 3 3 
Male 72 Epithelioid T3 N2 M0 T3 N2 M0 T3 N0 M0 3 3 3 
Male 66 Biphasic T3 N0 M0 T3 N0 M0 T3 N0 M0 3 3 3 
Female† 71† Epithelioid† T4 N2 M0† T4 N2 M0† T1a N0 M0† 4† 4† 1a† 
Male 68 Epithelioid T3 N0 M0 T2 N0 M0 T3 N0 M0 3 2 3 
Male 51 Epithelioid T3 N1 M0 T3 N0 M0 T1b N0 M0 3 3 1b 
Male 69 Epithelioid T2 N2 M0 T3 N2 M0 T2 N0 M0 3 3 2 
Male 71 Epithelioid T3 N2 M0 T1b N0 M0 T3 N2 M0 3 1b 3 
Male 73 Epithelioid T2 N0 M0 T2 N0 M0 T1b N0 M0 2 2 1b 
Male 66 Epithelioid T3 N0 M0 T2 N0 M0 T3 N0 M0 3 2 3 
 
Table 2. Summary of clinical and pathological staging 
†underwent neo-adjuvant chemotherapy between imaging and surgery 
PET=positron emission tomography; MRI=magnetic resonance imaging; CT= computed tomography; 
 TNM= tumour, nodes and metastasis AJCC malignant pleural mesothelioma staging system, 7th edition
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 Figure Legends 
 
Figure 1 
Axial CT (A), PET only (B) and fused FDG PET/CT (C) images in a 71 year old woman with 
epithelioid malignant pleural mesothelioma shows a metabolically active left basal pleural 
mass (arrows) with transdiaphragmatic invasion abutting the spleen, consistent with a T4 
tumour. Corresponding axial T1 Dixon water sequence post-gadolinium (D), PET only (E) and 
fused PET/MRI (F) images in the same patient shows similar appearance of the T4 tumour 
(arrows) with transdiaphragmatic invasion. 
 
Figure 2 
Axial CT (A), PET only (B) and fused FDG PET/CT (C) images in a 68 year old man with 
epithelioid malignant pleural mesothelioma demonstrates a metabolically active pleural 
nodule (arrows) in the right posterior hemithorax, staged as a T2 tumour on PET/CT. 
Corresponding axial T1 post-gadolinium Dixon water (D), PET only (E) and fused PET/MRI (F) 
images in the same patient show better delineation of the tumour (arrows), particularly on 
image (D), with local extension into the endothoracic fascia upstaging the patient to a T3 
tumour, confirmed at surgery. 
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Figure 3 
Axial CT (A) and fused FDG PET/CT (B) images in a patient with malignant pleural 
mesothelioma shows intense tracer uptake at a nodular focus of high attenuation talc 
accumulation (arrows) in the left medial basal hemithorax. Axial PET only image (C) from a 
PET/MRI study in the same patient shows corresponding intense tracer uptake in the same 
location (arrow), but without evidence of restricted diffusion seen on an inverted b900 DWI 
image (D, arrow) in the same location. 
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Figure 4 
Axial CT (A) and fused FDG PET/CT (B) images in a patient with malignant pleural 
mesothelioma shows increased FDG uptake at a linear focus of high density talc 
accumulation (arrows) in the right lateral basal hemithorax. Axial PET only image (C) from a 
PET/MRI study in the same patient shows corresponding elevated FDG uptake (arrow), with 
a lack of diffusion restriction in the same region on an inverted b900 DWI image (D, arrow). 
 
 
 
